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A B S T R A C T
Purpose
Although previous studies have implicated a variety of hormone-related risk factors in the etiology
of male breast cancers, no previous studies have examined the effects of endogenous hormones.
Patients and Methods
Within the Male Breast Cancer Pooling Project, an international consortium comprising 21
case-control and cohort investigations, a subset of seven prospective cohort studies were able to
contribute prediagnostic serum or plasma samples for hormone quantitation. Using a nested
case-control design, multivariable unconditional logistic regression analyses estimated odds ratios
and 95% CIs for associations between male breast cancer risk and 11 individual estrogens and
androgens, as well as selected ratios of these analytes.
Results
Data from 101 cases and 217 matched controls were analyzed. After adjustment for age and date
of blood draw, race, and body mass index, androgens were found to be largely unrelated to risk,
but circulating estradiol levels showed a significant association. Men in the highest quartile had an
odds ratio of 2.47 (95% CI, 1.10 to 5.58) compared with those in the lowest quartile (trend P 
.06). Assessment of estradiol as a ratio to various individual androgens or sum of androgens
showed no further enhancement of risk. These relations were not significantly modified by either
age or body mass index, although estradiol was slightly more strongly related to breast cancers
occurring among younger (age  67 years) than older men.
Conclusion
Our results support the notion of an important role for estradiol in the etiology of male breast
cancers, similar to female breast cancers.
J Clin Oncol 33:2041-2050. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Male breast cancer is a rare condition, comprising
only approximately 1% of all breast malignancies.1
Given its rarity, it has been difficult to study, and its
etiology remains elusive. Genetic risk factors, in-
cluding relations with familial history and BRCA
gene mutations,2 are well established, but other en-
vironmental risk factors are less clear.
Femalebreast cancer iswell recognizedasbeing
influenced by hormonal factors.3 It seems the same
is true formale breast cancer, given that studies have
identified high risks related to obesity,4-10 physical
inactivity,4,9,10 exogenous hormone use,11-14 and
diabetes.7,15 Investigations have also reported high
risks among patients with Klinefelter syndrome
(condition characterized by 46-XXY karyotype and
relative excesses of estrogens in relation to
androgens)16-18 as well as gynecomastia (enlarge-
ment of male mammary glands often associated
with hormonal perturbations).8 Collectively,
these findings emphasize the need for assessing
the roles of endogenous hormones in relation to
male breast cancers. High levels of both estrogens
and androgens have been implicated in female
breast cancer,19,20 but studies have not yet been
conducted to assess their roles in the etiology of
male breast cancer.
Werecently reportedresults regardinghormone-
related risk factors from the Male Breast Cancer
Pooling Project, a consortium of 21 case-control
and cohort investigations.5 From seven of the con-
tributing cohort studies, we were able to access pre-
diagnostic serum or plasma samples, from which
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hormones could be measured. We report herein the results of this
analysis, in which we were able to assess male breast cancer risk in
relation to various estrogens and androgens and their ratios.
PATIENTS AND METHODS
Study Population
Male breast cancer cases andmatched controls were derived from seven
cohorts (Fig 1) that had been part of the Male Breast Cancer Pooling Project
andcould contributeprediagnostic serumorplasma samples.21-27These stud-
ies contributed deidentified data and biologic materials after institutional
review board and data-sharing agreement approvals. Breast cancer cases were
required to be incident (ie, diagnosed after exposure assessment) but did not
have to be the first diagnosed cancer. Risk factor information was available
primarily from completed questionnaires, although in one study,23 such data
were obtained via linkage with population registries.
We asked each study to provide 40 controls per case matched on sex,
race, year of birth ( 1 year), year of cohort entry ( 1 year), and exit date
(diagnosis of cancer [excluding nonmelanoma skin cancer], death, loss to
follow-up, or end of follow-up  date of diagnosis of index case).5 If the
index case had  0.7 mL serum/plasma available for hormone quantita-
tion, we requested that two of the 40 controls be selected using the follow-
ing additional criteria:  0.7 mL serum/plasma available, year of blood
draw ( 1 year), and number of freeze/thaw cycles. We were unable to
identify a complete set of controls for all matched sets, and one study21
attempted to match three controls per case; thus, in total, there were 101
breast cancer cases and 217 controls.
Kaiser
United States
(N. CA)
28 Cases
73 Controls
81% White
Median (IQR)
Case Follow-Up 
Time:
27 yrs (18, 35 yrs)
Janus
Norway
26 Cases
52 Controls
100% White
Median (IQR)
Case Follow-Up 
Time:
17 yrs (11, 22 yrs)
EPIC
Europe
13 Cases
26 Controls
100% White
Median (IQR)
Case Follow-Up 
Time:
4 yrs (3, 8 yrs)
PLCO
United States 
(nationwide)
12 Cases
24 Controls
83% White
Median (IQR)
Case Follow-Up 
Time:
8 yrs (6, 11 yrs)
HPFS
United States 
(nationwide)
11 Cases
22 Controls
88% White
Median (IQR)
Case Follow-Up 
Time:
8 yrs (6, 12 yrs)
PHS
United States 
(nationwide)
10 Cases
18 Controls
100% White
Median (IQR)
Case Follow-Up 
Time:
9 yrs (8, 11 yrs)
MEC
United States 
(HI and CA)
2 Cases
1 Controls
100% White
Median (IQR)
Case Follow-Up 
Time:
1 yr (1, 1 yr)
Male Breast Cancer Pooling Project Hormone Cohorts
Fig 1. Cohort studies contributing biologic samples for endogenous hormone assays in Male Breast Cancer Pooling Project. EPIC, European Prospective
Investigation Into Cancer and Nutrition; HPFS, Health Professionals Follow-Up Study; IQR, interquartile range; MEC, Multiethnic Cohort Study of Diet and Cancer; N.
CA, northern California; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Screening Trial.
Acetate
Cholesterol
Pregnenolone
Progesterone 17α-Hydroxy-Pregnenolone
17α-Hydroxy-Progesterone DHEA Androstenediol
Androstenedione
3THDenoretsotseTenortsE α-diol 3α-diol-G*
Androstanedione ADT ADT-G
Estradiol
Fig 2. Schematic of sex steroid hor-
mone metabolism. Sex steroid hormones
that were quantitated are underlined. (*)
Note that only nine are underlined, but 11
assays were conducted; this is because
3-androstanediol glucuronide (3-diol-G)
was quantitated as separate metabolites
of 3-androstanediol-3 glucuronide and 3-
androstanediol-17 glucuronide. ADT, andro-
sterone; ADT-G, androsterone glucuronide;
DHEA, dehydroepiandrosterone; DHT,
dihydrotestosterone.
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Laboratory Analysis
In collaboration with the Pharmacogenomics Laboratory of Laval Uni-
versity,QuébecCity,Québec,Canada,wequantitatively assessed the following
unconjugated sex steroid hormones by gas chromatography–mass spectrom-
etry: dehydroepiandrosterone, androstenediol, androstenedione, testoster-
one, dihydrotestosterone (DHT), androsterone, estrone (E1), and estradiol
(E2).Using liquid chromatography–tandemmass spectrometry,wemeasured
glucuronide derivatives of androgens, namely 3-androstanediol-3 glucuro-
nide (3-diol-3G), 3-androstanediol-17 glucuronide (3-diol-17G), and an-
drosterone glucuronide (ADT-G). No sulfates are reported. These hormones
cover a wide array and key positions of the sex steroid biosynthesis pathway,
includingbothandrogensandestrogens (Fig2).Cases, theirmatchedcontrols,
and blinded quality control (QC) samples from each cohort were randomly
assigned throughout the batches withmatched sets assayed in the same batch.
At the time of random assignment, an additional four blinded QC samples
from the same two individuals were added to each batch. Results from these
QC samples were used to assess the assays across the entire study. Except for
3-diol-17G, overall coefficients of variance (CVs) ranged from 2.5% to
12.3%; for 3-diol-17G, the overall CV was 43.5% because of one outlier
observation.With this removed, the CV for 3-diol-17G was 5.0%.
Statistical Analysis
Toassess associationsbetweeneachhormoneandmalebreast cancer,we
used logistic regression models to estimate covariate-adjusted odds ratios
(ORs) and 95% CIs. Before these logistic regression analyses, we adjusted all
hormones to reduce the influence of study-related variability.28 Using all
participants with baseline (prediagnostic) quantitation, we regressed each
log-transformed hormone on study and age. Study betas were summed and
divided by the number of studies minus one. This value was subtracted from
each of the study betas to generate study-specific correction factors, which
were subtracted from the log-hormone concentrations to generate individual-
level, study-corrected log hormone concentrations.
Each exposure was assessed after being categorized into quartiles using
cut points based on the exposure distribution of all participants with baseline
hormone quantitation, as well as assessed as a continuous metric with stan-
dardization to half the value of the interquartile range, such that continuous
estimates of association were approximately per-quartile increase in expo-
sure.29 In addition to assessing individual exposures, we also assessed
combinations and ratios of hormones that were metabolically close. These a
priori–specified exposures included: E2 to testosterone ratio; testosterone to
DHT ratio; E1 to androstenedione ratio; E2 to E1 ratio; parent estrogens (E1
Table 1. Distributions of Examined Variables by Case-Control Status of Men Included in Male Breast Cancer Pooling Project (n  318)
Variable
Controls (n  217) Cases (n  101)
PMedian IQR Median IQR
Demographic†
Age at blood draw, years‡ .62
Mean 50.93 51.59
SD 11.62 11.57
Age at diagnosis or pseudodiagnosis, years‡ .56
Mean 67.72 66.91
SD 11.12 11.03
BMI, kg/m2 .94
Mean 25.79 25.62
SD 4.21 3.37
Diabetes, % 3.81 1.02 .18§
Family history of breast cancer, % 4.00 23.08 .07§
Ever smoked, % 67.36 52.31 .04§
Current smokers, % 26.39 18.46 .11§
Pack-years smoked 22.50 7.50 to 37.50 12.50 3.85 to 22.50 .03
Cigarette smoking duration, years 25.00 15.00 to 29.00 15.00 10.00 to 25.00 .14
Cigarette smoking intensity, cigarettes per
day
20.00 10.00 to 30.00 12.22 10.00 to 25.00 .03
Current alcohol consumption, % 81.54 89.66 .16§
Alcohol consumption, g/d 13.54 1.83 to 13.54 13.54 5.51 to 27.74 .18
Hormonal
DHEA, nmol/L 6.36 4.11 to 9.78 6.03 3.62 to 9.46 .63
Androstenediol, pmol/L 2,668.28 1,936.95 to 3,867.49 2,694.79 1,992.94 to 3,871.21 .96
Androstenedione, nmol/L 2.60 1.94 to 3.41 2.77 2.11 to 3.23 .61
Testosterone, nmol/L 13.07 10.02 to 16.40 14.09 10.39 to 17.05 .31
DHT, pmol/L 1,409.71 1,089.15 to 1,823.06 1,435.25 1,147.00 to 1,936.13 .53
3-diol-3G, nmol/L 2.97 2.22 to 4.35 2.74 2.03 to 4.21 .36
3-diol-17G, nmol/L 6.64 4.54 to 9.24 6.45 4.65 to 8.15 .57
ADT, pmol/L 674.84 508.92 to 894.94 645.90 489.70 to 866.17 .54
ADT-G, nmol/L 72.97 57.08 to 105.06 74.08 52.09 to 97.18 .44
Estrone, pmol/L 81.02 64.54 to 105.20 84.63 70.70 to 111.27 .22
Estradiol, pmol/L 64.09 50.69 to 84.82 73.08 57.28 to 87.46 .03
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide;
BMI, body mass index; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; IQR, interquartile range; SD, standard deviation.
Wilcoxon rank sum test, unless otherwise indicated.
†Demographic variables generally assessed at time of study entry.
‡Matching factors in study.
§2 test for statistical difference between cases and controls. Family history of breast cancer information was available for only 12% of the study subjects.
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Table 2. Unconditional Logistic Regression of Serum and Plasma Hormone Levels and Male Breast Cancer Risk
Variable Controls Cases OR 95% CI P Controls Cases OR† 95% CI P
DHEA, nmol/L
 3.96 54 31 1.00 Referent 50 30 1.00 Referent
3.96 to  6.07 54 21 0.67 0.34 to 1.35 .27 51 20 0.68 0.34 to 1.39 .29
6.07 to  9.44 54 27 0.86 0.42 to 1.76 .67 53 23 0.77 0.36 to 1.62 .49
 9.44 54 22 0.71 0.33 to 1.50 .37 45 19 0.74 0.34 to 1.62 .45
Continuous 216 101 0.90 0.60 to 1.33 .58 199 92 0.90 0.58 to 1.40 .65
Androstenediol, pmol/L
 2,040.95 54 24 1.00 Referent 49 21 1.00 Referent
2,040.95 to  2,866.19 54 25 1.09 0.55 to 2.16 .82 52 25 1.20 0.59 to 2.45 .61
2866.19 to  4,093.17 54 26 1.15 0.57 to 2.33 .69 52 22 1.09 0.52 to 2.29 .82
 4,093.17 54 26 1.13 0.55 to 2.32 .73 46 24 1.35 0.63 to 2.89 .44
Continuous 216 101 1.04 0.64 to 1.70 .88 199 92 1.28 0.75 to 2.20 .37
Androstenedione, nmol/L
 1.95 55 20 1.00 Referent 54 19 1.00 Referent
1.95 to  2.60 53 27 1.42 0.71 to 2.83 .32 47 27 1.64 0.81 to 3.33 .17
2.60 to  3.41 54 34 1.71 0.87 to 3.36 .12 48 28 1.65 0.81 to 3.35 .17
 3.41 54 20 0.99 0.47 to 2.07 .98 50 18 1.00 0.46 to 2.16 1.00
Continuous 216 101 1.04 0.64 to 1.70 .88 199 92 0.85 0.48 to 1.50 .57
Testosterone, nmol/L
 10.05 55 21 1.00 Referent 52 19 1.00 Referent
10.05 to  13.17 54 20 0.92 0.44 to 1.91 .82 51 19 0.97 0.45 to 2.09 .94
13.17 to  16.41 54 28 1.30 0.65 to 2.59 .46 49 26 1.39 0.67 to 2.88 .38
 16.41 53 32 1.49 0.75 to 2.95 .25 47 28 1.53 0.73 to 3.17 .26
Continuous 216 101 1.17 0.68 to 2.02 .57 199 92 1.18 0.64 to 2.17 .59
DHT, pmol/L
 1,070.34 55 22 1.00 Referent 51 20 1.00 Referent
1,070.34 to  1,391.97 54 25 1.12 0.56 to 2.24 .74 50 24 1.20 0.58 to 2.46 .62
1,391.97 to  1,800.11 54 25 1.13 0.57 to 2.26 .72 49 21 1.04 0.50 to 2.18 .92
 1,800.11 53 29 1.34 0.68 to 2.62 .40 49 27 1.31 0.64 to 2.70 .46
Continuous 216 101 1.17 0.75 to 1.83 .48 199 92 1.20 0.73 to 1.94 .47
3-diol-3G, nmol/L
 2.23 54 32 1.00 Referent 51 30 1.00 Referent
2.23 to  3.01 56 24 0.71 0.37 to 1.37 .30 54 20 0.63 0.32 to 1.26 .19
3.01 to  4.40 52 23 0.74 0.38 to 1.45 .38 47 21 0.81 0.40 to 1.63 .55
 4.40 54 22 0.67 0.34 to 1.34 .26 47 21 0.80 0.39 to 1.63 .53
Continuous 216 101 0.83 0.57 to 1.19 .30 199 92 0.94 0.66 to 1.35 .74
3-diol-17G, nmol/L
 4.49 54 23 1.00 Referent 49 20 1.00 Referent
4.49 to  6.56 53 28 1.26 0.64 to 2.48 .50 50 26 1.34 0.66 to 2.73 .42
6.56 to  9.24 55 29 1.25 0.63 to 2.47 .52 51 26 1.34 0.65 to 2.78 .43
 9.24 53 20 0.89 0.43 to 1.84 .76 48 19 1.06 0.49 to 2.29 .89
Continuous 215 100 0.98 0.65 to 1.46 .91 198 91 1.06 0.69 to 1.62 .79
ADT, pmol/L
 493.66 55 29 1.00 Referent 51 27 1.00 Referent
493.66 to  647.62 53 25 0.92 0.47 to 1.80 .81 51 22 0.85 0.42 to 1.72 .66
647.62 to  874.96 54 25 0.90 0.46 to 1.75 .75 50 24 0.93 0.47 to 1.86 .84
 874.96 54 22 0.83 0.41 to 1.71 .62 47 19 0.84 0.39 to 1.81 .65
Continuous 216 101 1.10 0.71 to 1.69 .68 199 92 1.04 0.61 to 1.75 .89
ADT-G, nmol/L
 54.96 53 31 1.00 Referent 49 30 1.00 Referent
54.96 to  70.27 54 19 0.60 0.29 to 1.22 .16 53 16 0.52 0.24 to 1.10 .09
70.27 to  101.09 54 30 0.94 0.48 to 1.82 .85 49 27 0.95 0.47 to 1.89 .88
 101.09 54 20 0.64 0.30 to 1.35 .24 47 18 0.69 0.31 to 1.50 .35
Continuous 215 100 0.76 0.48 to 1.21 .25 198 91 0.81 0.49 to 1.35 .42
Estrone, pmol/L
 67.00 53 22 1.00 Referent 49 20 1.00 Referent
67.00 to  84.45 53 21 0.94 0.46 to 1.93 .87 47 19 0.96 0.45 to 2.05 .92
84.45 to  108.18 52 25 1.13 0.55 to 2.30 .74 47 23 1.12 0.53 to 2.38 .76
 108.18 53 32 1.36 0.66 to 2.79 .40 51 30 1.32 0.63 to 2.79 .47
Continuous 211 100 1.22 0.69 to 2.17 .49 194 92 1.17 0.65 to 2.10 .60
continued on following page
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plus E2); E2 to sumofADT-G, 3-diol-3G, 3-diol-17G, andDHT ratio; and
parent estrogens (E1 plus E2) to sum of ADT-G, 3-diol-3G, 3-diol-17G,
and DHT ratio.
We performed both conditional and unconditional analyses of the
data. Conditional models using original or study-adjusted hormone val-
ues, and unconditional models using original hormone values with model
adjustment for study, did not materially alter the results. Therefore, we
present results from the unconditional analyses using the study-adjusted
hormone values. In these analyses, we adjusted for race, date of blood draw
(continuous calendar years), and age at blood draw (continuous years).
Modeling dates or ages as categorical, instead of continuous, variables had
minimal effects on risk. We also assessed whether adjustment for study,
body mass index (BMI), family history of breast cancer, diabetes, cigarette
smoking (ever v never, currency, pack-years, duration, and intensity), and
alcohol consumption (currency and grams consumed per day) changed
OR estimates by 10%. None of these covariates consistently altered the
estimates obtained, but we included BMI as a continuous variable in the
fully adjusted model, given previous evidence that this is associated with
both male breast cancer risk and hormone levels and because adjustment
resulted in slight modifications of risk. Because we did not have information
on Klinefelter syndrome or gynecomastia from any studies, we could not
measurepotential confoundingeffects.Weassessedwhether relationsbetween
hormones and male breast cancer were modified by several risk factors by
performing likelihood ratio tests of nestedmodels with andwithout a hormo-
ne–risk factor interaction term. Heterogeneity was assessed in the same way
using a hormone-study interaction term.All testswere two sided, andP values
 .05 were considered statistically significant. Analyses were conducted using
STATA software (version 13; STATA, College Station, TX).
RESULTS
Among the 101male breast cancer cases and 217 controls, the average
age at blood drawwas 51.6 and 50.9 years, respectively (Table 1). The
mean age at diagnosis among cases was 66.9 years.
A family history of breast cancer in a first-degree relative was
more common among the cases than the controls, whereas therewere
nomajor differences with respect tomean BMI or history of diabetes.
Cases were significantly less likely than controls to report a history of
cigarette smoking but somewhat more likely to report having con-
sumed alcohol. Quantitation of the primary sex steroid hormones
revealed levels that would be expected from amiddle-agemale popu-
lation usingmass spectrometry technologies.30-32
Among the controls, androgen levels declined significantly with
age at blood draw, whereas estrogen levels increased (Appendix Table
A1, online only). In addition, BMI affected many of the hormones,
with higher BMI associated with lower androgen and somewhat
higher E2 levels. Substantial and significant correlations were found
between E2 and E1 (r  0.74), testosterone and DHT (r  0.74),
testosterone and androstenediol (r 0.54), testosterone and andro-
stenedione (r 0.53), and androstenedione and androstenediol (r
0.47). E2was significantly correlatedwith testosterone (r 0.50), but
correlationsbetweenother androgens andestrogenswereweaker, and
many were not statistically significant. Hormone concentrations
among controls were similar across studies (Appendix Table A2, on-
line only).
Table 2 summarizes risks associatedwith hormone analytes after
adjustment for race, date at blood draw, and age at blood draw—and
then in addition for BMI. Although there were not major differences
in the two sets of ORs, we chose to focus on the more fully adjusted
estimates, which in some instances were based on slightly reduced
numbers, given missing information on BMI. In general, andro-
gens were unrelated to risk, although there was a slightly increased
risk associated with elevated testosterone levels (ORQ4 v Q1, 1.53;
95% CI, 0.73 to 3.17; trend P  .59). This relation, however, was
much less impressive than those seen for estradiol, where those in
the highest quartile had an OR of 2.47 (95% CI, 1.10 to 5.58)
comparedwith those in the lowest quartile (trendP .06). Estrone
was not significantly related to risk (ORQ4 v Q1, 1.32; 95%CI, 0.63 to
2.79; trend P .60).
Further assessment of estrogens as a ratio to various individual
androgens or sum of androgens showed no additional discrimina-
tion of risk beyond that seen with the estrogens or androgens alone
(Table 3). We observed elevated, but not statistically significant,
risks for high levels of the ratio of E2 to testosterone (ORQ4 v Q1,
1.95; 95% CI, 0.90 to 4.24; trend P  .14). We also observed a
positive relation for the ratio of E2 to the sum of androgens down-
stream in the metabolic pathway from testosterone (ie, sum of
ADT-G, 3-diol-3G, 3-diol-17G, and DHT), with the highest
quartile providing an OR of 2.27 (95% CI, 0.98 to 5.29; trend P
.34). Although those with high summed E1 plus E2 showed some
risk elevation (ORQ4 v Q1, 1.57; 95%CI, 0.70 to 3.53; trendP .27),
there was no further distinction in risk when this measure was
examined as a ratio to testosterone levels or sum of androgens.
We assessed whether there was heterogeneity in hormone rela-
tions according to various identified risk factors (Table 4). We saw
somewhat stronger associations for most hormones among younger
(age 67 years) comparedwith oldermen (eg, highest v lowest quartile
forE2:OR, 3.17; 95%CI, 1.06 to 9.42 vOR,1.70; 95%CI, 0.49 to 5.91),
but the difference was not statistically significant (heterogeneity
Table 2. Unconditional Logistic Regression of Serum and Plasma Hormone Levels and Male Breast Cancer Risk (continued)
Variable Controls Cases OR 95% CI P Controls Cases OR† 95% CI P
Estradiol, pmol/L
 52.23 55 14 1.00 Referent 54 13 1.00 Referent
52.23 to  65.98 54 22 1.58 0.73 to 3.43 .25 47 17 1.50 0.66 to 3.44 .34
65.98 to  86.76 54 35 2.62 1.24 to 5.55 .01 48 33 3.00 1.37 to 6.56 .01
 86.76 53 30 2.28 1.04 to 5.00 .04 50 29 2.47 1.10 to 5.58 .03
Continuous 216 101 1.68 0.95 to 2.99 .08 199 92 1.79 0.98 to 3.25 .06
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide;
DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; OR, odds ratio.
Adjusted for race, date at blood draw, and age at blood draw. Continuous sex steroid hormone values were standardized to half of difference between 75th and
25th centiles of distribution before correlative analysis.
†Adjusted additionally for body mass index as continuous variable.
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P  .68). No substantial or consistent differences in hormone
relations were observed according to other potential risk factors,
including BMI (Table 4) or dichotomized exposures of cigarette
smoking or alcohol consumption (data not shown).
We also assessedwhether hormone associations differed accord-
ing towhether tumorswerediagnosedwithinorafter10yearsofblood
draw, but these analyses revealed nodistinctive differences (Appendix
Table A3, online only). Analyses that specifically excluded cases diag-
nosed within the first 3 years after blood draw also showed no major
risk differences (data not shown).
DISCUSSION
In this apparent first-time assessment, we found that male breast
cancer risk was influenced by prediagnostic endogenous estradiol.
Circulating androgen levels did not seem to be associated with much
risk alteration; thus,whenwe examined estradiol in relation to andro-
gens, therewasnoadditional enhancementof riskbeyond that already
seen with estradiol levels.
In observing a relation of male breast cancer with high estradiol
levels, results are consistent with those for postmenopausal female
Table 3. Unconditional Logistic Regression of Serum and Plasma Hormones and Male Breast Cancer Risk
Variable Controls Cases OR 95% CI P Controls Cases OR† 95% CI P
Estradiol to testosterone ratio
 0.004 55 21 1.00 Referent 50 16 1.00 Referent
0.004 to  0.005 54 24 1.15 0.57 to 2.32 .70 47 23 1.57 0.73 to 3.38 .24
0.005 to  0.007 53 24 1.19 0.58 to 2.45 .64 50 23 1.45 0.66 to 3.16 .36
 0.007 54 32 1.57 0.78 to 3.13 .20 52 30 1.95 0.90 to 4.24 .09
Continuous 216 101 1.42 0.83 to 2.43 .20 199 92 1.57 0.86 to 2.87 .14
Testosterone to DHT ratio
 0.088 55 19 1.00 Referent 51 18 1.00 Referent
0.088 to  0.105 53 34 1.82 0.92 to 3.61 .08 52 32 1.73 0.85 to 3.50 .13
0.105 to  0.127 54 19 0.97 0.46 to 2.06 .95 48 16 0.92 0.42 to 2.03 .84
 0.127 54 29 1.49 0.74 to 3.01 .26 48 26 1.54 0.74 to 3.21 .25
Continuous 216 101 0.89 0.55 to 1.43 .62 199 92 0.92 0.57 to 1.50 .74
Estrone to androstenedione ratio
 0.025 53 20 1.00 Referent 47 17 1.00 Referent
0.025 to  0.033 53 26 1.29 0.64 to 2.62 .48 48 25 1.45 0.68 to 3.08 .33
0.033 to  0.042 53 22 1.09 0.51 to 2.32 .82 48 19 1.06 0.47 to 2.38 .89
 0.042 52 32 1.67 0.79 to 3.56 .18 51 31 1.70 0.75 to 3.82 .20
Continuous 211 100 1.18 0.71 to 1.96 .51 194 92 1.17 0.69 to 1.98 .56
Estradiol to estrone ratio
 0.679 53 21 1.00 Referent 52 18 1.00 Referent
0.679 to  0.818 53 28 1.35 0.68 to 2.70 .39 46 25 1.61 0.77 to 3.35 .20
0.818 to  0.942 52 20 1.00 0.48 to 2.07 .99 50 19 1.13 0.53 to 2.42 .75
 0.942 53 31 1.56 0.79 to 3.08 .20 46 30 1.99 0.98 to 4.06 .06
Continuous 211 100 1.49 0.75 to 2.97 .26 194 92 1.92 0.89 to 4.17 .10
Sum of estrone plus estradiol
 123.23 53 18 1.00 Referent 51 16 1.00 Referent
123.23 to  153.58 53 18 0.98 0.45 to 2.11 .96 46 17 1.14 0.51 to 2.56 .74
153.58 to  195.12 53 37 2.02 1.00 to 4.12 .05 47 33 2.15 1.02 to 4.54 .04
 195.12 52 27 1.48 0.68 to 3.24 .32 50 26 1.57 0.70 to 3.53 .27
Continuous 211 100 1.40 0.78 to 2.51 .26 194 92 1.38 0.76 to 2.51 .29
Estradiol to sum of ADT-G, 3-diol-3G, 3-diol-17G, and DHT ratio
 0.0005 54 18 1.00 Referent 48 15 1.00 Referent
0.0005 to  0.0008 54 20 1.17 0.55 to 2.49 .69 49 18 1.18 0.53 to 2.66 .68
0.0008 to  0.0011 54 25 1.49 0.70 to 3.19 .30 51 23 1.50 0.66 to 3.37 .33
 0.0011 52 36 2.34 1.05 to 5.20 .04 49 34 2.27 0.98 to 5.29 .06
Continuous 214 99 1.20 0.86 to 1.69 .29 197 90 1.19 0.83 to 1.70 .34
Sum of estrone plus estradiol to sum of ADT-G, 3-diol-3G,
3-diol-17G, and DHT ratio
 0.0011 53 15 1.00 Referent 47 12 1.00 Referent
0.0011 to  0.0016 52 28 1.98 0.94 to 4.19 .07 48 27 2.21 0.99 to 4.93 .05
0.0016 to  0.0023 53 21 1.43 0.64 to 3.23 .39 48 19 1.51 0.63 to 3.65 .35
 0.0023 51 34 2.45 1.06 to 5.65 .04 49 32 2.38 0.98 to 5.80 .06
Continuous 209 98 1.09 0.78 to 1.51 .62 192 90 1.05 0.75 to 1.47 .76
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT-G, androsterone glucuronide; DHT, dihydrotestos-
terone; OR, odds ratio.
Adjusted for race, date at blood draw, and age at blood draw. Continuous sex steroid hormone values were standardized to half of difference between 75th and
25th centiles of distribution before correlative analysis.
†Adjusted additionally for body mass index as continuous variable.
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breast cancer.19,20,33-36 Interestingly, the magnitude of risk associated
with high levels of estrogens is similar for female and male breast
cancers, being on the order of two- to three-fold for the highest versus
lowest quartiles of estradiol levels. Although estrogen-mediated carci-
nogenesis is not well understood, potential mechanisms include mu-
tagenic action and stimulation of cell proliferation, which may
increase risk of neoplastic transformation and/or neoplastic progres-
sion.37,38
Although the etiologic role of androgens inmale breast cancer is
unclear, studies inwomen support associations independent of estro-
gens.19,20,36 Androgens may increase breast cancer risk directly by
increasing cell growth and proliferation or indirectly by peripheral
conversions toestrogenswithinanumberof tissues, includingadipose
and breast tissues.39 Although androgens are a likely relevant physio-
logicmechanismwith respect to thedevelopmentof estrogen receptor
(ER) –responsive tumors, we did not have complete information on
either ERs or androgen receptors for the tumors studied and thus
could not differentiate risks according to tumor subtype. On the basis
of other studies,40 we can assume thatmost of themale breast cancers
we studied would have been ER positive and probably androgen
receptor positive. Although it would have been of interest to examine
hormone relations according to hormone receptor status of the tu-
mors, it is noteworthy that some recent studies of female breast cancer
have found hormone relationships to prevail for both hormone
receptor–positive and –negative tumors,41 suggesting that hormones
may act through molecular pathways that do not directly involve the
receptors found within the tumor itself.
The incidenceofmalebreast cancer is approximately100 lower
than thatof femalebreast cancer,which likely reflects sexdifferences in
breast cancer pathogenesis, including the numbers and types of cells
available for carcinogenic transformation.42 Gynecomastia is a recog-
nized risk factor for male breast cancer, and it is believed to develop
mainly because of a disequilibrium between free estrogen and andro-
gen in breast tissue.43We had no information on the development of
gynecomastia and thus could not determine whether the effects of
estrogens onmale breast cancerweremediated throughmore tissue at
risk. However, data from the case-control studies that contributed
data to this pooling project5 and that collected information on gyne-
comastia indicated that it was a fairly rare event. This would support
that high levels of estrogens could be a biomarker of risk even in the
absence of diagnosed gynecomastia.
It has been proposed thatmale breast cancermay arise as a result
of a high ratio of estrogens to androgens.44 This speculation derives
mainly fromfindings that patientswithKlinefelter syndromeare at an
elevated risk ofmale breast cancer. Such patients, during adolescence,
begin to exhibit elevated levels of gonadotropins and decreased levels
of testosterone, resulting in their characteristic body proportions and
gynecomastia.17 In adults, low testosterone levels are a cardinal feature
of Klinefelter syndrome,45 along with high estradiol levels from over-
expressionof aromataseCYP19.46However, our results only infer that
the ratio of estradiol to testosterone and the sumof various androgens
maybe associatedwithmalebreast cancer; noneof these analyseswere
statistically significant at P .05.
Table 4. Unconditional Logistic Regression Analyses of Selected Hormones and Male Breast Cancer According to Age and BMI
Variable
Age at Diagnosis BMI
 67 Years  67 Years  25.07  25.07
No. of
Exposed
Cases OR 95% CI
No. of
Exposed
Cases OR 95% CI
No. of
Exposed
Cases OR† 95% CI
No. of
Exposed
Cases OR† 95% CI
Testosterone, nmol/L
 10.02 7 1.00 Referent 12 1.00 Referent 7 1.00 Referent 12 1.00 Referent
10.02 to  13.07 12 1.45 0.48 to 4.39 7 0.65 0.21 to 2.02 9 1.31 0.40 to 4.29 10 0.83 0.30 to 2.32
13.07 to  16.40 15 1.82 0.63 to 5.28 11 1.12 0.38 to 3.29 13 1.64 0.54 to 4.98 13 1.39 0.51 to 3.82
 16.40 16 2.08 0.71 to 6.11 12 1.10 0.38 to 3.21 16 2.07 0.69 to 6.24 12 1.26 0.46 to 3.49
Continuous 50 1.32 0.57 to 3.02 42 0.98 0.39 to 2.44 45 1.41 0.64 to 3.13 47 1.01 0.39 to 2.64
Estradiol, pmol/L
 50.69 7 1.00 Referent 6 1.00 Referent 9 1.00 Referent 4 1.00 Referent
50.69 to  64.09 11 2.06 0.70 to 6.11 6 0.91 0.24 to 3.45 10 1.65 0.57 to 4.77 7 1.51 0.37 to 6.12
64.09 to  84.82 19 3.56 1.27 to 9.94 14 2.43 0.72 to 8.16 13 2.53 0.89 to 7.17 20 3.81 1.94 to 13.86
 84.82 13 3.17 1.06 to 9.42 16 1.70 0.49 to 5.91 13 2.20 0.74 to 6.57 16 3.47 0.92 to 13.11
Continuous 50 3.08 1.21 to 7.84 42 1.21 0.53 to 2.75 45 1.66 0.75 to 3.69 47 2.32 0.90 to 5.96
Estradiol to sum of ADT-G, 3-diol-3G,
3-diol-17G, and DHT ratio
 0.0005 12 1.00 Referent 3 1.00 Referent 8 1.00 Referent 7 1.00 Referent
0.0005 to  0.0007 11 0.94 0.36 to 2.47 7 1.46 0.29 to 7.36 10 1.11 0.37 to 3.34 8 1.49 0.44 to 5.10
0.0007 to  0.0010 13 1.38 0.52 to 3.66 10 1.35 0.29 to 6.32 9 1.54 0.46 to 5.18 14 1.45 0.47 to 4.48
 0.0010 12 2.71 0.97 to 7.61 22 1.94 0.40 to 9.30 16 2.06 0.63 to 6.74 18 2.89 0.81 to 10.24
Continuous 48 1.65 0.88 to 3.09 42 1.01 0.65 to 1.56 43 1.37 0.74 to 2.57 47 1.10 0.71 to 1.69
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT-G, androsterone glucuronide; BMI, body mass index;
DHT, dihydrotestosterone; OR, odds ratio.
Adjusted for race, date at blood draw, age at blood draw, and BMI (continuous). Continuous sex steroid hormone values were standardized to half of difference
between 75th and 25th centiles of distribution before correlative analysis.
†Adjusted for race, date at blood draw, and age at blood draw.
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In postmenopausal female breast cancer, there is a high correla-
tion between BMI and estrogen levels, specifically free estradiol lev-
els.47 Although estradiol seems to remain a significant risk factor after
adjustment for BMI, the reverse is apparently not true; the association
of BMI with postmenopausal breast cancer in two studies entirely
disappeared after adjustment for free estradiol levels.48,49 In addition,
there is evidence in female breast cancer that exogenous estrogens50-52
have stronger effects on relative risks in thin women (eg, BMI 25
kg/m2), supporting that obese women have high estrogen levels that
prevent additional effects of other hormones.
These findings in women therefore stimulated our interest in
evaluating confoundingandeffectmodificationsofhormone levels by
BMI in men. However, we did not find that there were large differ-
ences in hormone relations after adjustment for BMI, nor did we find
that hormone relations varied substantially by BMI level. This may
reflect that hormones are not as strongly influenced by BMI in men
compared with women, although we did find some evidence of vari-
ations of hormone levels by BMI, particularly androgens, which were
inversely correlated, as has been noted by others.53-55 However, we
could not specifically assess relationswith free testosterone, given that
we did not measure sex hormone–binding globulin (SHBG). Free
testosterone may be more influenced by BMI than total testosterone,
because as SHBG levels decrease, the levels of free testosterone in-
crease, requiring less total testosterone tomaintain the feedback loop.
A similar relationwithBMIhas been seen amongwomenwith respect
to free versus total estradiol levels.48
Our results did suggest some possible effectmodification of hor-
mones by age at development of breast cancer, with estradiol being
more strongly related to younger- than older-onset cancers. Although
female breast cancer is recognized as showing distinctive clinical and
risk factordifferencesbyageatdiagnosis,56much less isknownregard-
ing these parameters for male breast cancer. One large series recently
reported that younger patients with male breast cancer had types of
tumors that are generally associatedwith a poor prognosis in women,
including ER- and/or progesterone receptor–negative tumors and
humanepidermalgrowthreceptor2–positive tumors.40 It is, however,
unclear whether these or other tumor characteristics would be influ-
enced by endogenous hormones.
This study had a number of strengths but some limitations as
well. Although this is the only prospective study to our knowledge to
assess endogenoushormones in relation tomalebreast cancer risk, the
numberof cases foranalysiswasmodest, reflecting thegeneral rarityof
this disease. Sampleswere collectedbeforediagnosis, oftentimesmany
yearsandatvarying timesbeforediagnosis.Wehadno informationon
SHBG, and although we had information on various risk factors, we
did not have access to some parameters that would have been of
interest, including BRCA status, gynecomastia, and Klinefelter syn-
drome. Finally, we lacked information on clinical parameters, includ-
ing hormone receptors.
In conclusion, in this investigation to assess the role of endoge-
nous hormones in the etiology of male breast cancer, we found, as in
postmenopausal female breast cancer, a strong relation with estradiol
levels.Androgensweremuch less importantpredictors, andasa result,
the ratio of estrogens to androgens was not as important as has been
previously speculated. Future studiesmay benefit from a focus on the
mediating effects of estrogens on breast cancer among men with
gynecomastia and/or Klinefelter syndrome.
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GLOSSARY TERMS
logistic regression analysis: a multivariable regression
model in which the log of the odds of a time-fixed outcome event
(eg, 30-day mortality) or other binary outcome is related to a
linear equation.
logistic regressionmodel: a multivariable prediction model in
which the log of the odds of a time-fixed outcome event or other binary
outcome is related to a linear equation.
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Appendix
The principal investigators from each of the European Prospective Investigation IntoCancer andNutrition centers that contributed
cases were: Heiner Boeing, Rudolph Kaaks (Germany); Göran Hallmans, Jonas Manjer (Sweden); Timothy J. Key, Nick Wareham
(United Kingdom); Kim Overvad, Anne Tjønneland (Denmark); Domenico Palli, Paolo Vineis, Rosario Tumino (Italy); Maria José
Sánchez (Spain); and Antonia Trichopoulou (Greece).
Table A1. Spearman Correlation Coefficients Among Sex Steroid Hormone Measures in MBCPP Controls (n  217)
Hormone DHEA Androstenediol Androstenedione Testosterone DHT 3-diol-3G 3-diol-17G ADT ADT-G E1 E2
Age at
Blood
Draw
BMI
(kg/m2)
DHEA 1.00
Androstenediol 0.61 1.00
Androstenedione 0.55 0.47 1.00
Testosterone 0.20 0.54 0.53 1.00
DHT 0.15 0.37 0.34 0.74 1.00
3-diol-3G 0.33 0.30 0.26 0.11 0.02 1.00
3-diol-17G 0.16 0.24 0.08 0.15 0.09 0.53 1.00
ADT 0.71 0.48 0.56 0.31 0.31 0.28 0.06 1.00
ADT-G 0.57 0.43 0.27 0.16 0.08 0.58 0.46 0.50 1.00
E1 0.11 0.12 0.42 0.33 0.22 0.00 0.07 0.27 0.03 1.00
E2 0.03 0.21 0.27 0.50 0.34 0.06 0.11 0.14 0.02 0.74 1.00
Age at blood draw 0.49 0.34 0.05 0.10 0.14 0.02 0.19 0.29 0.42 0.44 0.40 1.00
BMI, kg/m2 0.10 0.14 0.16 0.19 0.34 0.10 0.19 0.23 0.02 0.09 0.15 0.14 1.00
NOTE. Bold font indicates significance at .05 level.
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide;
BMI, body mass index; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; E1, estrone; E2, estradiol; MBCPP, Male Breast Cancer Pooling Project.
Table A2. Hormone Medians and IQRs for Controls by Study
Hormone Variable
EPIC (n  26) HPFS (n  22) Janus (n  52) Kaiser (n  73)
Median IQR Median IQR Median IQR Median IQR
DHEA, nmol/L 5.79 4.13 to 7.43 3.30 2.34 to 6.36 9.98 6.54 to 13.70 6.06 4.41 to 8.31
Androstenediol, pmol/L 2,440.17 1,865.78 to 2,960.50 1,876.82 1,188.21 to 2,668.28 3,781.97 2,780.06 to 5,192.30 2,544.48 1,934.24 to 3,635.27
Androstenedione, nmol/L 2.63 2.08 to 3.14 2.21 1.65 to 3.27 2.71 2.05 to 3.38 2.43 1.76 to 2.93
Testosterone, nmol/L 12.70 11.25 to 15.94 14.00 10.71 to 16.86 14.51 11.39 to 17.92 12.04 8.35 to 14.59
DHT, pmol/L 1,602.91 1,300.63 to 2,107.15 1,281.16 1,015.90 to 1,846.84 1,494.93 1,169.02 to 1,878.91 1,292.41 1,027.23 to 1,727.27
3-diol-3G, nmol/L 2.95 2.24 to 3.82 2.50 1.72 to 3.54 3.87 2.74 to 5.55 2.70 2.09 to 3.88
3-diol-17G, nmol/L 6.24 4.42 to 8.89 5.24 4.11 to 11.16 6.89 4.44 to 9.44 6.88 4.96 to 9.24
ADT, pmol/L 641.06 508.92 to 757.44 493.78 428.11 to 674.84 757.82 521.93 to 1,077.61 695.56 532.82 to 951.34
ADT-G, nmol/L 63.97 53.53 to 78.85 55.75 44.42 to 75.08 99.62 74.08 to 131.94 72.41 57.31 to 108.61
Estrone, pmol/L 80.15 69.56 to 118.07 91.56 85.31 to 98.95 67.52 56.19 to 86.56 75.59 59.55 to 94.89
Estradiol, pmol/L 62.92 54.74 to 78.03 79.31 64.09 to 85.00 53.62 42.57 to 68.93 63.92 47.95 to 80.31
Hormone Variable
MEC (n  2) PHS (n  18) PLCO (n  24)
Median IQR Median IQR Median IQR
DHEA, nmol/L 4.20 3.90 to 4.50 4.27 3.49 to 5.93 7.04 4.28 to 10.28
Androstenediol, pmol/L 1,304.15 1,184.63 to 1,423.67 1,926.17 1,455.32 to 3,000.90 2,847.75 2,197.83 to 3,899.09
Androstenedione, nmol/L 3.42 3.00 to 3.83 2.08 1.81 to 3.39 3.68 2.77 to 4.44
Testosterone, nmol/L 13.15 10.02 to 16.28 10.09 8.31 to 14.49 15.96 13.17 to 20.28
DHT, pmol/L 546.01 272.83 to 819.19 1,295.29 860.57 to 1,496.19 1,596.62 1,376.37 to 2,440.40
3-diol-3G, nmol/L 2.21 1.78 to 2.64 2.98 2.34 to 3.84 2.58 1.99 to 4.66
3-diol-17G, nmol/L 1.99 1.99 to 1.99 6.41 4.84 to 7.43 7.32 5.38 to 9.75
ADT, pmol/L 593.30 582.25 to 604.35 577.84 408.15 to 658.13 763.86 615.76 to 844.96
ADT-G, nmol/L 36.85 12.84 to 60.86 62.86 56.20 to 85.96 71.63 58.31 to 91.18
Estrone, pmol/L 112.66 98.49 to 126.84 75.14 56.41 to 110.16 138.34 121.59 to 159.80
Estradiol, pmol/L 74.17 51.13 to 97.22 53.23 39.06 to 69.11 98.38 91.11 to 107.55
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide;
BMI, body mass index; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; EPIC, European Prospective Investigation Into Cancer and Nutrition; HPFS,
Health Professionals Follow-Up Study; IQR, interquartile range; MEC, Multiethnic Cohort Study of Diet and Cancer; PHS, Physicians’ Health Study; PLCO, Prostate,
Lung, Colorectal and Ovarian Screening Trial.
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Table A3. Logistic Regression of Hormones and Male Breast Cancer Stratified by Interval Between Blood Draw and Diagnosis
Variable
Interval  10 Years Interval  10 Years
Controls Cases OR 95% CI P Controls Cases OR 95% CI P
DHEA, nmol/L
 3.96 25 18 1.00 Referent 29 13 1.00 Referent
3.96 to  6.07 20 8 0.50 0.17 to 1.46 .20 34 12 0.83 0.32 to 2.15 .69
6.07 to  9.44 21 9 0.50 0.16 to 1.52 .22 33 18 1.32 0.49 to 3.52 .59
 9.44 9 4 0.54 0.13 to 2.17 .38 45 17 0.91 0.34 to 2.43 .86
Continuous 75 39 0.64 0.24 to 1.69 .37 141 60 0.96 0.62 to 1.48 .84
Androstenediol, pmol/L
 2,040.95 21 12 1.00 Referent 33 12 1.00 Referent
2,040.95 to  2,866.19 21 10 0.83 0.29 to 2.37 .73 33 15 1.31 0.52 to 3.30 .57
2,866.19 to  4,093.17 18 9 0.88 0.29 to 2.65 .81 36 16 1.34 0.52 to 3.45 .54
 4,093.17 15 8 0.94 0.30 to 3.00 .92 39 17 1.26 0.49 to 3.26 .64
Continuous 75 39 0.84 0.33 to 2.14 .71 141 60 1.09 0.60 to 1.98 .77
Androstenedione, nmol/L
 1.95 23 9 1.00 Referent 32 11 1.00 Referent
1.95 to  2.60 16 12 1.96 0.66 to 5.79 .22 37 14 1.07 0.42 to 2.69 .89
2.60 to  3.41 16 12 1.83 0.61 to 5.49 .28 38 21 1.55 0.64 to 3.72 .33
 3.41 20 6 0.74 0.22 to 2.48 .62 34 14 1.15 0.45 to 2.97 .77
Continuous 75 39 0.59 0.23 to 1.54 .29 141 60 1.32 0.74 to 2.38 .35
Testosterone, nmol/L
 10.05 14 6 1.00 Referent 41 15 1.00 Referent
10.05 to  13.17 23 8 0.80 0.23 to 2.82 .73 31 10 0.88 0.34 to 2.26 .79
13.17 to  16.41 18 12 1.54 0.46 to 5.17 .48 36 16 1.16 0.49 to 2.73 .73
 16.41 20 13 1.49 0.45 to 4.97 .52 33 19 1.56 0.67 to 3.61 .30
Continuous 75 39 0.82 0.31 to 2.15 .68 141 60 1.46 0.75 to 2.87 .27
DHT, pmol/L
 1,070.34 14 8 1.00 Referent 41 14 1.00 Referent
1,070.34 to  1,391.97 19 12 1.10 0.35 to 3.46 .87 35 12 1.00 0.41 to 2.47 .99
1,391.97 to  1,800.11 18 8 0.78 0.23 to 2.61 .69 36 16 1.28 0.55 to 2.99 .57
 1,800.11 24 11 0.80 0.26 to 2.49 .70 29 18 1.84 0.79 to 4.32 .16
Continuous 75 39 0.84 0.42 to 1.68 .63 141 60 1.59 0.87 to 2.89 .13
3-diol-3G, nmol/L
 2.23 22 16 1.00 Referent 32 16 1.00 Referent
2.23 to  3.01 22 7 0.43 0.15 to 1.27 .13 34 17 0.96 0.41 to 2.23 .92
3.01 to  4.40 18 8 0.61 0.20 to 1.84 .38 34 14 0.74 0.30 to 1.80 .51
 4.40 13 8 0.83 0.26 to 2.62 .74 41 13 0.58 0.24 to 1.42 .23
Continuous 75 39 0.92 0.56 to 1.51 .74 141 60 0.70 0.41 to 1.17 .17
3-diol-17G, nmol/L
 4.49 20 8 1.00 Referent 34 15 1.00 Referent
4.49 to  6.56 22 12 1.48 0.47 to 4.70 .51 31 16 1.15 0.49 to 2.73 .75
6.56 to  9.24 15 10 1.77 0.54 to 5.76 .34 40 18 1.00 0.43 to 2.33 1.00
 9.24 17 8 1.18 0.34 to 4.06 .80 36 11 0.68 0.27 to 1.72 .42
Continuous 74 38 1.04 0.48 to 2.22 .92 141 60 0.89 0.54 to 1.48 .66
ADT, pmol/L
 493.66 20 17 1.00 Referent 35 11 1.00 Referent
493.66 to  647.62 25 8 0.36 0.12 to 1.03 .06 28 17 2.10 0.83 to 5.34 .12
647.62 to  874.96 18 9 0.57 0.20 to 1.62 .29 36 15 1.44 0.57 to 3.68 .44
 874.96 12 5 0.45 0.13 to 1.62 .22 42 17 1.46 0.56 to 3.77 .44
Continuous 75 39 0.45 0.14 to 1.45 .18 141 60 1.32 0.82 to 2.13 .26
ADT-G, nmol/L
 54.96 23 18 1.00 Referent 30 13 1.00 Referent
54.96 to  70.27 22 8 0.43 0.15 to 1.25 .12 32 11 0.77 0.28 to 2.10 .61
70.27 to  101.09 20 9 0.52 0.18 to 1.52 .23 34 21 1.32 0.53 to 3.26 .55
 101.09 9 4 0.51 0.13 to 2.09 .35 45 14 0.69 0.26 to 1.83 .46
Continuous 74 39 0.60 0.24 to 1.50 .27 141 59 0.77 0.44 to 1.35 .37
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Table A3. Logistic Regression of Hormones and Male Breast Cancer Stratified by Interval Between Blood Draw and Diagnosis (continued)
Variable
Interval  10 Years Interval  10 Years
Controls Cases OR 95% CI P Controls Cases OR 95% CI P
Estrone, pmol/L
 67.00 12 7 1.00 Referent 41 15 1.00 Referent
67.00 to  84.45 16 5 0.55 0.14 to 2.22 .40 37 16 1.17 0.50 to 2.71 .72
84.45 to  108.18 19 9 0.84 0.23 to 3.07 .80 33 16 1.39 0.58 to 3.31 .46
 108.18 27 18 1.20 0.35 to 4.08 .77 26 12 1.21 0.47 to 3.11 .69
Continuous 74 39 1.14 0.47 to 2.76 .77 137 59 1.24 0.58 to 2.68 .58
Estradiol, pmol/L
 52.23 12 3 1.00 Referent 43 11 1.00 Referent
52.23 to  65.98 19 7 1.56 0.33 to 7.44 .58 35 15 1.67 0.68 to 4.12 .26
65.98 to  86.76 20 13 3.14 0.68 to 14.39 .14 34 21 2.55 1.06 to 6.16 .04
 86.76 24 16 3.34 0.71 to 15.80 .13 29 13 1.86 0.71 to 4.87 .21
Continuous 75 39 1.48 0.59 to 3.71 .40 141 60 1.80 0.85 to 3.79 .12
Estradiol to testosterone ratio
 0.004 17 4 1.00 Referent 38 17 1.00 Referent
0.004 to  0.005 18 11 2.66 0.70 to 10.09 .15 36 13 0.80 0.34 to 1.88 .61
0.005 to  0.007 20 10 2.27 0.56 to 9.21 .25 33 14 0.95 0.40 to 2.28 .91
 0.007 20 14 3.22 0.85 to 12.27 .09 34 16 1.10 0.47 to 2.58 .83
Continuous 75 39 1.48 0.63 to 3.46 .36 141 60 1.31 0.64 to 2.67 .45
Testosterone to DHT ratio
 0.088 18 6 1.00 Referent 37 13 1.00 Referent
0.088 to  0.105 20 14 2.13 0.63 to 7.20 .22 33 18 1.56 0.66 to 3.69 .31
0.105 to  0.127 21 8 1.14 0.31 to 4.16 .85 33 11 0.95 0.37 to 2.42 .92
 0.127 16 11 2.11 0.61 to 7.34 .24 38 18 1.28 0.54 to 3.02 .58
Continuous 75 39 0.91 0.51 to 1.61 .74 141 60 0.81 0.36 to 1.84 .62
Estrone to androstenedione ratio
 0.025 15 11 1.00 Referent 40 20 1.00 Referent
0.025 to  0.033 19 13 — — 38 15 0.77 0.34 to 1.76 .54
0.033 to  0.042 27 15 — — 34 8 0.44 0.16 to 1.18 .10
 0.042 27 15 — — 25 16 1.42 0.57 to 3.55 .45
Continuous 74 39 1.14 0.54 to 2.42 .73 137 59 1.21 0.59 to 2.47 .60
Estradiol to estrone ratio
 0.679 20 7 1.00 Referent 33 13 1.00 Referent
0.679 to  0.818 17 12 2.06 0.65 to 6.56 .22 36 16 1.23 0.50 to 3.00 .65
0.818 to  0.942 18 10 1.64 0.51 to 5.32 .41 34 9 0.72 0.27 to 1.93 .51
 0.942 19 10 1.55 0.48 to 5.05 .47 34 21 1.66 0.71 to 3.87 .24
Continuous 74 39 1.81 0.49 to 6.59 .37 137 59 1.42 0.62 to 3.26 .40
Sum of estrone plus estradiol
 123.23 12 5 1.00 Referent 41 13 1.00 Referent
123.23 to  153.58 15 7 1.19 0.29 to 4.90 .81 38 11 0.89 0.35 to 2.26 .81
153.58 to  195.12 22 11 1.29 0.34 to 4.96 .71 31 26 2.81 1.20 to 6.58 .02
 195.12 25 16 1.72 0.43 to 6.84 .44 27 9 1.04 0.37 to 2.94 .93
Continuous 74 39 1.28 0.52 to 3.18 .59 137 59 1.46 0.67 to 3.16 .34
Estradiol to sum of ADT-G, 3-diol-3G,
3-diol-17G, and DHT ratio
 0.0005 11 4 1.00 Referent 43 14 1.00 Referent
0.0005 to  0.0008 14 2 0.43 0.07 to 2.88 .39 40 16 1.29 0.55 to 3.04 .56
0.0008 to  0.0011 21 12 1.99 0.48 to 8.31 .35 33 13 1.34 0.52 to 3.42 .55
 0.0011 27 20 3.23 0.69 to 15.08 .14 25 16 2.25 0.84 to 5.97 .10
Continuous 73 38 1.17 0.77 to 1.78 .47 141 59 1.41 0.77 to 2.57 .26
Sum of estrone plus stradiol to sum
ADT-G, 3-diol-3G, 3-diol-17G,
and DHT ratio
 0.0011 9 4 1.00 Referent 44 11 1.00 Referent
0.0011 to  0.0016 17 4 0.56 0.11 to 2.81 .48 35 22 2.72 1.13 to 6.56 .03
0.0016 to  0.0023 18 10 1.45 0.33 to 6.37 .62 35 11 1.36 0.49 to 3.76 .55
 0.0023 28 20 2.19 0.49 to 9.74 .30 23 14 2.71 0.94 to 7.85 .07
Continuous 72 38 1.09 0.74 to 1.60 .66 137 58 1.22 0.63 to 2.38 .56
Abbreviations: 3-diol-3G, 3-androstanediol-3 glucuronide; 3-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide;
DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; OR, odds ratio.
Adjusted for race, date at blood draw, and age at blood draw. Continuous sex steroid hormone values were standardized to half of difference between 75th and
25th centiles of distribution before correlative analysis.
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